Mainland China's Growing Appetite for Hong Kong Biotech: A New Era of Investment?
Mainland Chinese funds have been increasing their stakes in Hong Kong biotech firms, driven by attractive valuations and a surge in licensing deals.
On July 2, E Fund Management, the largest mutual fund manager in China, purchased an additional 91,500 shares in Biocytogen Pharmaceuticals, bringing its stake to 7%.